- Company
- Astrazeneca-SK supplying Diabetics worth $100 million/year
- by Eo, Yun-Ho Dec 22, 2019 09:51pm
- AstraZeneca and SK announced that the drug was manufactured and produced under the partnership signed by the two companies in January 2018 and is being supplied to 3 million people with diabetes in 98 countries. The agreement contributed to SK's successful entry into the global biopharmaceutical manufacturing and production business and th
- Company
- SK Holdings reaffirms partnership with AstraZeneca
- by Lee, Seok-Jun Dec 20, 2019 06:36am
- On Dec. 19, SK Holdings CEO Jang Dong-hyun met with Chairman Leif Johansson of AstraZeneca at the SK Group Headquarters, Seoul. At the meeting, SK Biotek and AstraZeneca announced they have been supplying diabetes treatment to about hundred countries since their partnership deal signed in January 2018. The two companies stated their partnership
- Company
- Companies done submitting metformin record, what now?
- by Chon, Seung-Hyun Dec 20, 2019 06:32am
- Pharmaceutical companies in Korea have completed submitting usage record of metformin medicine to the government body. The industry seems to be patiently waiting for the government’s follow-up action on finding impurity in metformin-containing drugs. According to pharmaceutical industry insiders on Dec. 18, pharmaceutical companies hav
- Company
- Anti-ulcer market fluctuates from impurity risk aftermath
- by Chon, Seung-Hyun Dec 19, 2019 06:41am
- Apparently, the anti-ulcer treatment market is still shaken with the impurity contamination risk. The market volume of nizatidine drugs, with a recent discovery of impurity exceeding an acceptable level, subsided within a month. A several cases of impurity found in products brought down the H2 receptor antagonist prescription volume, but rather
- Company
- Punishment for rebate MD is on the rise
- by Jung, Hye-Jin Dec 19, 2019 06:35am
- A series of tougher penalties rulings against the medical personnel's illegal rebates have been issued. Once caught, the ruling to collect the full rebate collection has become the trend. Analysts say that the justice department increase the level of rebate punishment. Dailypharm's analysis of the major rulings on drug rebates on the
- Company
- New flu season to spark up another round of competition
- by Kim, Jin-Gu Dec 18, 2019 02:25pm
- The flu season in Korea has just arrived for the year. Korea Centers for Disease Control and Prevention (KCDC) issued a flu warning on November 15. The season is to last until May next year. The new flu season is to start up even more fierce competition in the flu treatment market. The market leader, Tamiflu (oseltamivir) sales has
- Company
- ‘Noltec’, domestic new drug sets a new record
- by Chon, Seung-Hyun Dec 18, 2019 06:25am
- Il Yang's anti-ulcer drug 'Noltec' is breaking a record every day. Continued upward trend after expanding indications, the company benefited from the reflection of impurities from competing drugs. According to UBIST, a drug research agency on the 17th, Noltech's outpatient prescriptions last month increased by 16.7% to &8361;2.9 billion. By No
- Company
- Chong Kun Dang in talks over approved Xofluza
- by Kim, Jin-Gu Dec 18, 2019 06:25am
- Xofluza (baloxavir), a follow-on drug for influenza patient treating Tamiflu (oseltamivir), has been recently approved the Korean health regulator, and is now in talks with Chong Kun Dang Pharmaceutical about the marketing deal in Korea. Korean Ministry of Food and Drug Safety (MFDS) has granted an approval on commercialization of Roch
- Company
- Oraxol by Hanmi apply US license
- by An, Kyung-Jin Dec 18, 2019 06:24am
- The commercialization of the anti-cancer drug 'Oraxol', a technology exported by Hanmi, is imminent. Hanmi's US partner Athenex unveiled its Phase III clinical results for patients with metastatic breast cancer and announced its intention to approve the FDA in early next year. Some assessments suggest that some indicators, such as gastrointestin
- Company
- Korean companies now having long year-end holiday
- by Lee, Seok-Jun Dec 17, 2019 12:33pm
- The Korean pharmaceutical industry is starting to adopt the long year-end holiday season to wrap up the year around Christmas and to start fresh from the New Year. Boryung Pharmaceutical and other Korean companies are having a long holiday for the first time this year. Multinational pharmaceutical companies are starting their long holiday se
